Advanced search
Publication Cover
Melanoma Management Volume 3, 2016 - Issue 4
Submit an article Journal homepage
43
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Vaccine Therapy + Dasatinib for the Treatment of Patients with Stage IIIB–IV Melanoma

Ahmad A Tarhini1 Department of Medicine,University of Pittsburgh School of Medicine,Pittsburgh,PA15213,USA;2 Melanoma Program of the University of Pittsburgh Cancer Institute,Pittsburgh,PA15213,USAView further author information
,
Hussein Tawbi3 Department of Melanoma Medical Oncology,University of Texas MD Anderson Cancer Center,Houston,TX77030,USAView further author information
&
Walter J Storkus2 Melanoma Program of the University of Pittsburgh Cancer Institute,Pittsburgh,PA15213,USA;4 Department of Dermatology,University of Pittsburgh School of Medicine,Pittsburgh,PA15213,USA;5 Department of Immunology,University of Pittsburgh School of Medicine,Pittsburgh,PA15213,USA;6 Department of Pathology,University of Pittsburgh School of Medicine,Pittsburgh,PA15213,USA;7 Department of Bioengineering,University of Pittsburgh School of Medicine,Pittsburgh,PA15213,USACorrespondence[email protected]
View further author information
Pages 251-254 | Received 15 May 2016, Accepted 03 Jun 2016, Published online: 29 Nov 2016

References

  • Cancer Facts and Figures 2016. American Cancer Society, Atlanta, GA, USA (2016). www.cancer.org/acs/groups/content/@research/documents/document/acspc-047079.pdf
  • Balch CM , GershenwaldJE, SoongSJet al. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol.27 (36), 6199 – 6206 (2007).
  • Harries M , MalvehyJ, LebbeCet al. Treatment patterns of advanced malignant melanoma (stage III–IV) – a review of current standards in Europe. Eur. J. Cancer60, 179 – 189 (2016).
  • Larkin J , Chiarion-SileniV, GonzalezRet al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med.373 (1), 23 – 34 (2015).
  • Ascierto ML , MeleroI, AsciertoPA. Melanoma: from incurable beast to a curable bet. The success of immunotherapy. Front. Oncol.5, 152 (2015).
  • Zarour HM . Reversing T-cell dysfunction and exhaustion in cancer. Clin. Cancer Res.22 (8), 1856 – 1864 (2016).
  • Melero I , GaudernackG, GerritsenWet al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat. Rev. Clin. Oncol.11 (9), 509 – 524 (2014).
  • Chi M , DudekAZ. Vaccine therapy for metastatic melanoma: systematic review and meta-analysis of clinical trials. Melanoma Res.21 (3), 165 – 174 (2011).
  • Salerno EP , SheaSM, OlsonWCet al. Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund’s adjuvant, with or without peptide. Cancer Immunol. Immunother.62 (7), 1149 – 1159 (2013).
  • Zhang Y , ErtlHC. Starved and asphyxiated: how can CD8+ T cells within a tumor microenvironment prevent tumor progression. Front. Immunol.7, 32 (2016).
  • Ohta A . A metabolic immune checkpoint: adenosine in tumor microenvironment. Front. Immunol.7, 109 (2016).
  • Zhao X , BoseA, KomitaHet al. Vaccines targeting tumor blood vessel antigens promote CD8+ T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice. J. Immunol.188 (4), 1782 – 1788 (2012).
  • Chi Sabins N , TaylorJL, FabianKPet al. DLK1: a novel target for immunotherapeutic remodeling of the tumor blood vasculature. Mol. Ther.21 (10), 1958 – 1968 (2013).
  • Huang Y , GoelS, DudaDG, FukumuraD, JainRK. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res.73 (10), 2943 – 2948 (2013).
  • Kwilas AR , DonahueRN, TsangKY, HodgeJW. Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy. Cancer Cell Microenviron.2 (1), e677 (2015).
  • Lowe DB , BoseA, TaylorJLet al. Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma. Oncoimmunology3 (1), e27589 (2014).
  • Maes H , KuchnioA, PericAet al. Tumor vessel normalization by chloroquine independent of autophagy. Cancer Cell26 (2), 190 – 206 (2014).
  • BMS-354825 , Bristol-Myers Squibb Investigator Brochure, Version no. 5, Version date: 26-Jan-2006. BMS Document Control No. 930003494.
  • ClinicalTrials Database: NCT01876212 . https://clinicaltrials.gov/ct2/show/NCT01876212
  • Kluger HM , DudekAZ, McCannCet al. A phase 2 trial of dasatinib in advanced melanoma. Cancer117, 2202 – 2208 (2011).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.